Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (491)	3/2/2005 2:54:45 PM
From: Icebrg	Read Replies (1) \| Respond to of 946

Ian Next week we will know if they met that SPA's primary endpoint or not. That will be all that matters. The details at ASCO will be interesting, but just noise. The signal seems to be due already next week. Erik

To: Ian@SI who wrote (491)	3/2/2005 3:42:36 PM
From: former_pgs	Read Replies (1) \| Respond to of 946

I'm probably the only person who cares about little details such as this, but... The response rate in the blended ST3 population is 29%. At this point, it is the investigator assessed response rate and so it will probably drop once an independent review is done. In that regard, it will be interesting to see the independently verified response rate versus the investigator assessed 29%. One of the pitfalls when i look at oncology companies is trying to determine how reliable the response rates are in the small, investigator initiated trials... this before and after data set for Stellar 3 may give us a "conversion factor" to apply for future trials. That data will probably be available at ASCO. That's my small diversion for now :-)